Home / Market News / $INO

$INO news and market catalysts

The 18 most recent market catalysts affecting $INO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

18 catalysts 4 high impact 10 bullish 5 bearish Biotechnology
Nov 12, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Maintains Buy Rating on Inovio Pharmaceuticals and Raises Price Target
Piper Sandler analyst Edward Tenthoff reaffirmed a 'Buy' rating for Inovio Pharmaceuticals and raised the price target from $4 to $6. This analyst upgrade suggests increased confid…
Nov 11, 2026 Corporate Catalyst Bullish Impact 75
Innovotech Reports Third Quarter 2026 Financial Results
Innovotech Inc. reported its third-quarter 2026 financial results, showing a revenue of $661,762. The most significant development is the 40% sequential reduction in net loss to $3…
Nov 11, 2026 Corporate Catalyst Neutral Impact 75
Inovio Pharmaceuticals Reports Third Quarter 2026 Financial Results
Inovio Pharmaceuticals reported a net loss of $49.2 million for Q3 2026, an increase from $45.5 million in Q3 2025, which is generally a negative indicator for investors. While R&D…
Nov 7, 2026 Corporate Catalyst Bullish Impact 65
Jefferies Maintains Inovio Pharmaceuticals at Buy, Raises Price Target to $8
Investment firm Jefferies maintained its 'Buy' rating on Inovio Pharmaceuticals and substantially increased its price target from $3 to $8. This analyst action reflects continued c…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
Innovotech Inc. Signs National Distribution Agreement with Healthmark
Innovotech Inc. has announced a national distribution agreement with Healthmark Services Ltd. for its InnovoTEST™ hazardous drug wipe testing kits. This partnership is significant …
Nov 2, 2026 Corporate Catalyst Bullish Impact 75
HC Wainwright Upgrades Inovio Pharmaceuticals to Buy
HC Wainwright upgraded Inovio Pharmaceuticals to a 'Buy' rating from 'Neutral' and set a $5 price target. This upgrade is a direct consequence of the recent FDA accelerated approva…
Oct 31, 2026 Corporate Catalyst Bullish Impact 95
Inovio Receives FDA Accelerated Approval for VOCERYQ to Treat Recurrent Respiratory Papillomatosis
Inovio Pharmaceuticals received FDA accelerated approval for VOCERYQ, its plasmid DNA-based immunotherapy for recurrent respiratory papillomatosis. This is a major positive catalys…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Innovotech Inc. Establishes New Banking Partnership with ATB Financial
Innovotech Inc. has announced a new banking relationship with ATB Financial, which includes a $500,000 revolving operating line of credit and a $100,000 corporate credit card facil…
Oct 21, 2026 Corporate Catalyst Bullish Impact 65
Inovio Pharmaceuticals Secures $80.4 Million Judgment in Litigation Against VGXI and GeneOne
Inovio Pharmaceuticals has won a significant legal battle, securing an $80.4 million judgment against VGXI and GeneOne. This includes $61.8 million in compensatory damages and $18.…
Oct 20, 2026 Corporate Catalyst Bearish Impact 75
Inovio Wins $80,416,101 Judgment Against VGXI And GeneOne, Says Defendants’ Financial Condition Likely To Impair Collection
This headline represents a significant corporate catalyst for Inovio, as an $80 million judgment could substantially improve its balance sheet and fund ongoing R&D or operations. T…
Aug 13, 2026 Corporate Catalyst Bullish Impact 65
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3
Jefferies analyst Roger Song upgraded Inovio Pharmaceuticals (INO) from a 'Hold' to a 'Buy' rating and significantly raised the price target from $1.80 to $3.00. This positive re-e…
Aug 13, 2026 Corporate Catalyst Bullish Impact 75
Inovio Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results.
This headline represents a strong corporate catalyst for Inovio Pharmaceuticals, driving its share price higher. Better-than-expected earnings often signal efficient operations, su…
Aug 12, 2026 Corporate Catalyst Bearish Impact 92
Inovio Pharmaceuticals Q2 EPS $(0.07) Beats $(0.22) Estimate
Inovio Pharmaceuticals (INO) announced Q2 EPS of $(0.07), significantly outperforming the analyst estimate of $(0.22). This 68.18% beat, coupled with an 88.52% improvement over las…
Aug 6, 2026 Corporate Catalyst Bearish Impact 75
Inovalis REIT Q2 FFO $(0.01) Beats $(0.10) Estimate, Sales $2.934M Down From $4.419M YoY
Inovalis REIT's Q2 earnings report presents a mixed picture. While the company's FFO loss of $(0.01) per share significantly beat the analyst consensus of $(0.10), indicating bette…
Aug 3, 2026 Corporate Catalyst Bearish Impact 65
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4
Piper Sandler's reiteration of an 'Overweight' rating suggests the analyst still sees upside potential for Inovio Pharmaceuticals, but the simultaneous reduction in the price targe…
Jul 30, 2026 Corporate Catalyst Neutral Impact 85
Reported Earlier, INOVIO Prices $20.0M Public Offering Of 21,052,632 Common Shares At $0.95 Per Share With Accompanying Warrants
This public offering is a significant corporate catalyst for INOVIO. The issuance of over 21 million new shares at a price below the market value (implied by the $20M total) will l…
Jul 30, 2026 Corporate Catalyst Bearish Impact 85
Inovio Stock Falls 21% After Hours: Here's What's Going On
Inovio Pharmaceuticals (INO) priced a public offering of 21.05 million shares and 42.11 million warrants at $0.95 per unit, aiming to raise $20 million. This move, while securing c…
Jul 29, 2026 Corporate Catalyst Neutral Impact 65
INOVIO Pharmaceuticals Announces Proposed Public Offering Of Shares And Warrants
INOVIO Pharmaceuticals is seeking to raise capital through a public offering of its common stock and warrants. This type of offering typically leads to dilution for current shareho…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.